1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance [TA287] Published date: 26 June 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • 9 Appraisal Committee members and NICE project team
  • 10 Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download
    • Save
    • Save as PDF
    • Save as ePub
    • Save as eBook

Guidance

  • Next

1 Guidance

1 Guidance

1.1 Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

  • National Institute for Health and Care Excellence (NICE)

  • Next
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • NICE and the public
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.